UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended June 30, ~~2018~~2019

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________.

Commission File Number:0-12305

REPRO MED SYSTEMS, INC.

(Exact name of registrant as specified in its charter)


New York	13-3044880
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)

24 Carpenter Road, Chester, New York	10918
(Address of Principal Executive Offices)	(Zip Code)

(845) 469-2042

(Registrant’s telephone number, including area code)

N/A

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol(s)	Name of each exchange on which registered
common stock, $0.01 par value	REPR	OTCQX

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. [X] Yes [ ] No

Indicate by check mark whether the registrant has submitted electronically ~~and posted on its corporate Web site, if any,~~ every Interactive Data File required to be submitted ~~and posted~~ pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


	Large accelerated filer [ ]	Accelerated filer [ ]
	Non-accelerated filer [ ]	Smaller reporting company [X]
	~~(Do not check if a smaller reporting company)~~	Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [ ] Yes [X] No

As of August ~~6, 2018, 38,195,214~~7, 2019, 38,383,980 shares of common stock, $0.01 par value per share, were outstanding, which excludes 2,737,231 shares of treasury stock.

REPRO MED SYSTEMS, INC.

TABLE OF CONTENTS


		PAGE

PART I– FINANCIAL INFORMATION

ITEM 1.	Financial Statements

	Balance Sheets as of June 30, ~~2018~~2019 (Unaudited) and December 31, ~~2017~~2018	3

	Statements of Operations (Unaudited) for the three and six months ended June 30, ~~2018~~2019 and ~~2017~~2018	4

	Statements of Cash Flows (Unaudited) for the six months ended June 30, ~~2018~~2019 and ~~2017~~2018	5

	Notes to Financial Statements	6

ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	1215

ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk	1621

ITEM 4.	Controls and Procedures	1721

PART II– OTHER INFORMATION

ITEM 1.	Legal Proceedings	21

ITEM 1A.	Risk Factors	23

ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	1723

ITEM 6.	Exhibits	1723

- 2 -

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

REPRO MED SYSTEMS, INC.

BALANCE SHEETS


	June 30,			December 31,			June 30,
	2018			2017			2019			December 31,
	(Unaudited)						(Unaudited)			2018
ASSETS

CURRENT ASSETS
Cash and cash equivalents	$	3,421,186		$	3,974,536		$	3,807,192		$	3,738,803
Certificate of deposit (restricted cash)		1,504,818			—
Certificates of deposit		159,462			263,269			—			1,517,927
Accounts receivable less allowance for doubtful accounts of $77,067 at June 30, 2018 and $77,067 at December 31, 2017		1,840,094			1,861,949
Accounts receivable less allowance for doubtful accounts of $37,299 at June 30, 2019 and $37,500 at December 31, 2018								3,293,196			1,425,854
Inventory		1,718,294			1,658,681			2,571,585			2,103,879
Prepaid expenses		255,888			170,739			257,320			246,591
TOTAL CURRENT ASSETS		8,899,742			7,929,174			9,929,293			9,033,054
Property and equipment, net		795,484			836,283			615,555			858,781
Patents, net of accumulated amortization of $220,340and $203,768 at June 30, 2018 and December 31, 2017, respectively		531,685			483,821
Patents, net of accumulated amortization of $260,812 and $239,581 at June 30, 2019 and December 31, 2018, respectively								747,106			632,156
Right of use assets, net								439,782			—
Deferred tax asset								—			1,466
Other assets		31,582			31,582			19,582			19,582
TOTAL ASSETS	$	10,258,493		$	9,280,860		$	11,751,318		$	10,545,039

LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES
Deferred capital gain - current	$	15,003		$	22,481		$	—		$	3,763
Accounts payable		711,947			454,398			530,380			453,498
Accrued expenses		539,473			658,060			1,034,830			688,649
Accrued payroll and related taxes		187,307			334,903			171,984			421,714
Accrued tax liability		91,488			115,854			—			16,608
Finance lease liability - current								4,295			—
Operating lease liability - current								133,417			—
TOTAL CURRENT LIABILITIES		1,545,218			1,585,696			1,874,906			1,584,232
Deferred capital gain – long term		—			3,762
Deferred tax liability		20,733			21,675			65,029			—
Finance lease liability, net of current portion								—			—
Operating lease liability, net of current portion								306,365			—
TOTAL LIABILITIES		1,565,951			1,611,133			2,246,300			1,584,232

STOCKHOLDERS’ EQUITY
Common stock, $0.01 par value; 75,000,000 shares authorized, 40,907,991 and 40,731,529 shares issued, 38,170,760 and 37,994,298 shares outstanding at June 30, 2018 and December 31, 2017, respectively		409,080			407,315
Common stock, $0.01 par value; 75,000,000 shares authorized, 41,121,211 and 40,932,911 shares issued, 38,383,980 and 38,195,680 shares outstanding at June 30, 2019 and December 31, 2018, respectively								411,212			409,329
Additional paid-in capital		4,358,618			4,216,718			5,144,749			4,595,214
Retained earnings		4,269,048			3,389,898			4,293,261			4,300,468
		9,036,746			8,013,931			9,849,222			9,305,011
Less: Treasury stock, 2,737,231 shares at June 30, 2018 and December 31, 2017		(344,204	)		(344,204	)
Less: Treasury stock, 2,737,231 shares at June 30, 2019 and December 31, 2018, respectively, at cost								(344,204	)		(344,204	)
TOTAL STOCKHOLDERS’ EQUITY		8,692,542			7,669,727			9,505,018			8,960,807
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	10,258,493		$	9,280,860		$	11,751,318		$	10,545,039

The accompanying notes are an integral part of these financial statements

- 3 -

REPRO MED SYSTEMS, INC.

STATEMENTS OF OPERATIONS (UNAUDITED)


	For the Three Months Ended						For the Six Months Ended						For the Three Months Ended						For the Six Months Ended
	June 30,						June 30,						June 30,						June 30,
	2018			2017			2018			2017			2019			2018			2019			2018

NET SALES	$	4,502,326		$	3,829,457		$	8,535,550		$	7,467,893		$	5,348,812		$	4,502,326		$	10,323,090		$	8,535,550
Cost of goods sold		1,762,742			1,532,158			3,330,142			3,068,639			1,873,148			1,762,742			3,799,472			3,330,142
Gross Profit		2,739,584			2,297,299			5,205,408			4,399,254			3,475,664			2,739,584			6,523,618			5,205,408

OPERATING EXPENSES
Selling, general and administrative		2,022,631			2,005,336			3,902,900			3,780,445			3,175,382			2,022,631			6,152,765			3,902,900
Research and development		23,963			24,840			33,811			70,746			178,235			23,963			280,194			33,811
Depreciation and amortization		75,978			76,781			150,556			151,662			86,169			75,978			169,820			150,556
Total Operating Expenses		2,122,572			2,106,957			4,087,267			4,002,853			3,439,786			2,122,572			6,602,779			4,087,267

Net Operating Profit		617,012			190,342			1,118,141			396,401
Net Operating Profit/(Loss)														35,878			617,012			(79,161	)		1,118,141

Non-Operating (Expense)/Income
(Loss)/Gain on currency exchange		(19,838	)		34,670			(10,414	)		51,744
Interest and other income		5,501			421			6,116			2,066
TOTAL OTHER (EXPENSE)/INCOME		(14,337	)		35,091			(4,298	)		53,810
Non-Operating Income/(Expense)
Loss on currency exchange														(1,235	)		(19,838	)		(10,925	)		(10,414	)
Gain on disposal of fixed asset, net														49,980			—			49,740			—
Interest, net and other income, net														18,243			5,501			35,723			6,116
TOTAL OTHER INCOME/(EXPENSE)														66,988			(14,337	)		74,538			(4,298	)

PROFIT BEFORE TAXES		602,675			225,433			1,113,843			450,211
INCOME/(LOSS) BEFORE TAXES														102,866			602,675			(4,623	)		1,113,843

Income Tax Expense		(126,952	)		(76,961	)		(234,693	)		(174,788	)		(24,683	)		(126,952	)		(2,584	)		(234,693	)

NET INCOME	$	475,723		$	148,472		$	879,150		$	275,423
NET INCOME/(LOSS)													$	78,183		$	475,723		$	(7,207	)	$	879,150

NET INCOME PER SHARE

Basic	$	0.01		$	—		$	0.02		$	0.01		$	0.00		$	0.01		$	0.00		$	0.02
Diluted	$	0.01		$	—		$	0.02		$	0.01		$	0.00		$	0.01		$	0.00		$	0.02

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING

Basic		38,100,040			37,825,209			38,058,500			37,799,981			38,353,000			38,100,040			38,279,718			38,058,500
Diluted		38,872,998			37,899,619			38,815,301			37,866,730			39,299,800			38,872,998			39,219,752			38,815,301

The accompanying notes are an integral part of these financial statements

- 4 -

REPRO MED SYSTEMS, INC.

STATEMENTS OF CASH FLOWS

(UNAUDITED)


	For the Six Months Ended						For the Six Months Ended
	June 30,						June 30,
	2018			2017			2019			2018

CASH FLOWS FROM OPERATING ACTIVITIES
Net Income	$	879,150		$	275,423
Adjustments to reconcile net income to net cash provided by/(used in) operating activities:
Amortization of deferred compensation cost		—			7,000
Net (Loss)/Income							$	(7,207	)	$	879,150
Adjustments to reconcile net (loss)/income to net cash (used in)/provided by operating activities:
Stock based compensation expense		94,170			41,479			529,538			94,170
Depreciation and amortization		150,556			151,662			169,820			150,556
Deferred capital gain - building lease		(11,240	)		(11,240	)		(3,763	)		(11,240	)
Deferred taxes		(941	)		12,937			66,494			(941	)
Provision for returns and doubtful accounts		—			(5,603	)
Gain on disposal of fixed asset								(49,740	)		—
Changes in operating assets and liabilities:
Decrease/(Increase) in accounts receivable		21,855			(597,699	)
(Increase)/Decrease in inventory		(59,613	)		94,177
(Increase)/Decrease in prepaid expense and other assets		(85,149	)		33,174
Increase/(Decrease) in accounts payable		257,549			(492,919	)
(Decrease)/Increase in accrued payroll and related taxes		(147,597	)		71,113
Decrease in accrued expense		(118,587	)		(12,207	)
(Decrease)/Increase in accrued tax liability		(24,366	)		161,851
NET CASH PROVIDED BY/(USED IN) OPERATING ACTIVITIES		955,787			(270,852	)
(Increase)/Decrease in accounts receivable								(1,867,342	)		21,855
Increase in inventory								(467,706	)		(59,613	)
Decrease/(Increase) in prepaid expense and other assets								44,874			(85,149	)
Increase in accounts payable								76,882			257,549
Decrease in accrued payroll and related taxes								(249,730	)		(147,597	)
Increase/(Decrease) in accrued expense								346,181			(118,587	)
Decrease in accrued tax liability								(72,210	)		(24,366	)
NET CASH (USED IN)/PROVIDED BY OPERATING ACTIVITIES								(1,483,909	)		955,787

CASH FLOWS FROM INVESTING ACTIVITIES
Payments for capital expenditures		(93,185	)		(89,437	)		(67,079	)		(93,185	)
Purchase of certificate of deposit (restricted cash)		(1,500,000	)		—
Reinvested earnings on certificate of deposit (restricted cash)		(4,818	)		—
Purchase of certificate of deposit								—			(1,500,000	)
Reinvested earnings on certificate of deposit								—			(4,818	)
Payments for patents		(64,436	)		(53,346	)		(136,182	)		(64,436	)
Proceeds/(reinvested earnings) from certificates of deposit		103,807			(1,196	)
NET CASH USED IN INVESTING ACTIVITIES		(1,558,632	)		(143,979	)
Proceeds on disposal of fixed asset								217,821			—
Proceeds from certificates of deposit								1,517,927			103,807
NET CASH PROVIDED BY/(USED IN) INVESTING ACTIVITIES								1,532,487			(1,558,632	)

CASH FLOWS FROM FINANCING ACTIVITIES
Stock issuances		51,250			—			24,700			51,250
Payment for cancelled shares		(1,755	)		(19,360	)		(2,820	)		(1,755	)
Purchase of treasury stock		—			(484	)
NET CASH PROVIDED BY/(USED) IN FINANCING ACTIVITIES		49,495			(19,844	)
Finance lease								(2,069	)		—
NET CASH PROVIDED BY FINANCING ACTIVITIES								19,811			49,495

NET DECREASE IN CASH AND CASH EQUIVALENTS		(553,350	)		(434,675	)
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS								68,389			(553,350	)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		3,974,536			3,417,183			3,738,803			3,974,536
CASH AND CASH EQUIVALENTS, END OF PERIOD	$	3,421,186		$	2,982,508		$	3,807,192		$	3,421,186

Supplemental Information
Cash paid during the periods for:
Interest	$	—		$	—		$	233		$	—
Taxes	$	260,000		$	—		$	—		$	260,000

NON-CASH FINANCING AND INVESTING ACTIVITIES
Issuance of common stock as compensation	$	67,500		$	67,500		$	212,898		$	67,500

The accompanying notes are an integral part of these financial statements

- 5 -

REPRO MED SYSTEMS, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

NOTE 1 NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NATURE OF OPERATIONS

REPRO MED SYSTEMS, INC. (the “Company”, ~~“RMS”,~~“RMS Medical” or “we”) designs, manufactures and markets proprietary portable and innovative medical devices primarily for the ambulatory infusion market ~~and emergency medical applications~~ as governed by the United States Food and Drug Administration (the “FDA”) quality and regulatory system and international standards for quality ~~management systems.~~system management. The Company operates as one segment.

FISCAL YEAR END

The Company’s fiscal year end is December 31.

BASIS OF PRESENTATION

The accompanying unaudited financial statements as of June 30, ~~2018,~~2019, have been prepared in accordance with generally accepted accounting principles and with instructions to SEC regulation S-X for interim financial statements.

In the opinion of the Company’s management, the financial statements contain all adjustments consisting of normal recurring accruals necessary to present fairly the Company’s financial position as of June 30, ~~2018,~~2019, and the results of operations and cash flow for the three and six ~~month~~months periods ended June 30, ~~2018,~~2019, and ~~2017.~~2018.

The results of operations for the ~~three and~~ six months ended June 30, ~~2018,~~2019 and ~~2017~~2018 are not necessarily indicative of the results to be expected for the full year. These interim financial statements should be read in conjunction with the financial statements and notes thereto of the Company and management’s discussion and analysis of financial condition and results of operations included in the Company’s Annual Report for the ~~year~~twelve months ended December 31, ~~2017,~~2018, as filed with the Securities and Exchange Commission on Form 10-K.

CASH AND CASH EQUIVALENTS

For purposes of the statement of cash flows, the Company considers all short-term investments with an original maturity of three months or less to be cash equivalents. The Company holds cash in excess of $250,000 at its depository, which exceeds the FDIC insurance limits and is, therefore, uninsured.

CERTIFICATES OF DEPOSIT

The certificate of deposit was recorded at cost plus accrued interest. The certificate of deposit earned interest at a rate of 1.73% and matured in May 2019, at which time the funds were moved into a money market account earning interest at 2.25%.

INVENTORY

Inventories of raw materials are stated at the lower of standard cost, which approximates average cost, or market value including allocable overhead. Work-in-process and finished goods are stated at the lower of standard cost or market value and include direct labor and allocable overhead.

PATENTS

Costs incurred in obtaining patents have been capitalized and are being amortized over the legal life of the patents.

INCOME TAXES

Deferred income taxes are provided using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences.

- 6 -

The Company believes that it has no uncertain tax positions requiring disclosure or adjustment. Generally, tax years starting with 2016 are subject to examination by income tax authorities.

PROPERTY, EQUIPMENT, AND DEPRECIATION

Property and equipment is stated at cost and is depreciated using the straight-line method over the estimated useful lives of the respective assets.

STOCK-BASED COMPENSATION

The Company maintains a stock option plan under which it grants stock options and has issued stock to certain executives, key employees and consultants. The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model. All options are charged against income at their fair value. The entire compensation expense of the award is recognized over the vesting period. Shares of stock granted are recorded at the fair value of the shares at the grant date.

USE OF ESTIMATES IN THE FINANCIAL STATEMENTS

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Important estimates include but are not limited to, asset lives, valuation allowances, inventory, and accruals.

REVENUE RECOGNITION

The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09—Revenue from Contracts with Customers, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. We adopted this ASU effective January 1, 2018 on a full retrospective basis. Adoption of this standard did not result in significant changes to our accounting policies, business processes, systems or controls, or have a material impact on our financial position, results of operations and cash flows or related disclosures. As such, prior period financial statements were not recast.

The Company’s revenues result from the sale of assembled products. We recognize revenues when shipment occurs and at which point the customer obtains control and ownership of the goods. Shipping costs generally are billed to customers and are included in sales.

The Company generally does not accept return of goods shipped unless it is a Company error. The only credits provided to customers are for defective merchandise. The Company warrants the syringe driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation. The costs under the warranty are expensed as incurred.

~~- 6 -~~

Provisions for distributor pricing and annual customer volume rebates are variable consideration and are recorded as a reduction of revenue in the same period the related sales are recorded or when it’s probable the annual growth target will be achieved. ~~The rebates~~Rebates are provided to distributors for the difference in selling price to distributor and pricing specified to select customers.

LEASES

In February 2016, the FASB issued a new standard related to leases to increase transparency and comparability among organizations by requiring the recognition of right-of-use (“ROU”) assets and lease liabilities on the balance sheet. Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by the Company for those leases classified as operating leases under current U.S. GAAP, while our accounting for capital leases remains substantially unchanged. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The standard became effective for us January 1, 2019. The standard had a material impact on our balance sheets, but did not have a material impact on our income statements. See NOTE 7 LEASES.

- 7 -

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

In June 2016, the FASB issued ASU No. 2016-13—Financial Instruments – Credit Losses (Topic 326); Measurement of Credit Losses on Financial Instruments, which amends guidance on reporting credit losses for assets held at amortized cost basis and available for sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available for sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. This ASU affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in this update are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption.

In ~~February 2016,~~August 2018, the FASB issued ASU No. ~~2016-02, Leases~~2018-13 Fair Value Measurement (Topic ~~842).~~820): Disclosure Framework – Changes to the Disclosure for Fair Value Measurement. The ~~main difference between the current requirement under GAAP and~~amendments in this ASU ismodify the ~~recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases. This ASU requires that a lessee recognize~~disclosure requirements on fair value measurements in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term (other than leases that meet the definition of a short-term lease). The liability will be equal to the present value of lease payments. The asset will beTopic 820 based on the ~~liability, subject to adjustment, such as for initial direct costs. For income statement purposes,~~concepts in the ~~FASB retained a dual model, requiring leases to be classified as either operating or finance. Operating leases will result~~Concepts Statement, including the consideration of costs and benefits. The amendments in straight-line expense (similar to current operating leases) while finance leases will result in a front-loaded expense pattern (similar to current capital leases). Classification will be based on criteria thatthis ASU are ~~largely similar to those applied in current lease accounting. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. This is~~ effective for ~~annual~~all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, ~~2018~~2019. The amendments on changes in unrealized gains and ~~early~~losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is ~~permitted. This ASU must be adopted using a~~permitted upon issuance of this ASU. An entity is permitted to early adopt any removed or modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the potential impactdisclosures upon issuance of this ASU and delay adoption of the additional disclosures until their effective date. The Company is assessing the impact of the adoption of the ASU on ~~our~~its financial statements, disclosure requirements and methods of adoption.

In August 2018, the FASB issued ASU No. 2018-15 Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. The amendments in this ASU align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). The accounting for the service element of a hosting arrangement that is a service contract is not affected by the amendments in this ASU. The amendments in this ASU are effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption of the amendments in this ASU is permitted, including adoption in any interim period, for all entities. The amendments in this ASU should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption.

The Company considers the applicability and impact of all recently issued accounting pronouncements. Recent accounting pronouncements not specifically identified in our disclosures are either not applicable to the Company or are not expected to have a material effect on our financial condition or results of operations.

~~STOCK-BASED COMPENSATION~~FAIR VALUE OF FINANCIAL INSTRUMENTS

The carrying amounts reported in the balance sheet for cash, trade receivables, accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments.

ACCOUNTING FOR LONG-LIVED ASSETS

The Company ~~maintains a long-term incentive stock benefit plan under which it grants stock options~~reviews its long-lived assets for impairment at least annually or whenever the circumstances and ~~stock to certain directors and key employees. The fair value~~situations change such that there is an indication that the carrying amounts may not be recoverable. As of ~~each option grant is estimated on~~June 30, 2019, the ~~date~~Company does not believe that any of ~~the grant using the Black-Scholes option-pricing model. All options~~its assets are charged against income at their fair value. The entire compensation expense of the award is recognized over the vesting period. Shares of restricted stock granted are recorded at the fair value of the shares at the grant date and are recognized over the vesting period.impaired.

RECLASSIFICATION

Certain reclassifications have been made to conform prior period data to the current presentation. These reclassifications had no effect on reported net income.

- 78 -

NOTE 2 RELATED PARTY TRANSACTIONS

~~On December 20, 2013,~~LEASED AIRCRAFT

From 1992 to 2018, we ~~executed~~leased an ~~agreement effective March 1, 2014, with~~aircraft from AMI Aviation, Inc., of which our former President and Chief Executive Officer, Andrew Sealfon, was a ~~Company director, Dr. Paul Mark Baker, to provide clinical research~~majority shareholder. The lease payments were zero and support services related to new and enhanced applications for the FREEDOM System. Authorized by the Board of Directors, the agreement provided for payment of 420,000 shares of common stock valued at $0.20 per share over a three-year period. Amortization was zero$3,876 for the three months ended June 30, ~~2018~~2019 and ~~2017,~~2018, respectively and zero and ~~$7,000~~$7,752 for the six months ended June 30, 2019 and 2018 ~~and 2017, respectively;~~respectively. Upon the ~~agreement is fully amortized.~~

~~On June 24, 2016, Cyril Narishkin, the Company’s former Chief Operating Officer, executed a~~ termination ~~and general release agreement, which terminated his previous consulting agreement, and resigned~~of Mr. Sealfon as an officer and director for personal reasons. Mr. Narishkin was compensated for services as a consultant through January 31, 2017 at a monthly rate of $16,000 per month for up to eight days of service a month upon request of the Company. Mr. Narishkin’s compensation was zero for the three months ended June 30, 2018 and 2017, respectively, and was zero and $16,000 for the six months ended June 30, 2018 and 2017, respectively.

~~In January 2017, Brad Sealfon, the son of Andrew Sealfon, a Company Director and former~~ President and Chief Executive Officer ~~consulted for~~on July 25, 2018, the Company in its production and quality departments and was compensated $5,184. In March 2017, Mr. Sealfon provided additional consulting as a principal of Stokequest, LLC for the Company in its marketing department and was compensated $2,000. Mr. Sealfon has not performed any consulting for the Company during the six months ended June 30, 2018.

~~LEASED AIRCRAFT~~

The Company leases an aircraft from a company controlled by Andrew Sealfon, a Company Director and former President and Chief Executive Officer. The lease payments were $3,876 for both three months ended June 30, 2018 and 2017, and $7,752 and $9,251 for the six months ended June 30, 2018 and 2017, respectively. The original lease agreement has expired and the Company is currently on a month-to-month basis for rental payments.ceased leasing this aircraft.

BUILDING LEASE

Mr. ~~Mark~~ Pastreich, a former director, is a principal in the entity that owns the building leased by ~~Company. The Company is in~~us for our corporate headquarters and manufacturing facility at 24 Carpenter Road, Chester, New York 10918. On February 28, 2019, we completed year twenty of a ~~twenty-year lease. With a~~twenty year lease with monthly lease ~~amount~~payments of $11,042, the lease payments were $33,126 for each of the three months ended June 30, 2018 and 2017 and $66,252 for each of the six months ended June 30, 2018 and 2017. The Company also paid property taxes for the three months ended June 30, 2018 and 2017 in the amount of $12,720 and $12,418, respectively, and $25,432 and $24,585 for the six months ended June 30, 2018 and 2017, respectively.$11,042. On November 14, 2017, ~~the Company~~we executed a lease extension, which calls for six month extensions beginning March 1, 2019 with the option to renew six times at a monthly lease amount of $12,088.

The lease payments were $36,264 and $33,126 for the three months ended June 30, 2019 and 2018, respectively, and $70,436 and $66,252 for the six months ended June 30, 2019 and 2018, respectively. The Company also paid property taxes in the amount of $12,989 and $12,720 for the three months ended June 30, 2019 and 2018, respectively and $25,416 and $25,432 for the six months ended June 30, 2019 and 2018, respectively.

NOTE 3 PROPERTY AND EQUIPMENT

Property and equipment consists of the following at:


	June 30, 2018			December 31, 2017			June 30, 2019			December 31, 2018

Land	$	54,030		$	54,030		$	—		$	54,030
Building		171,094			171,094			—			171,094
Vehicles		60,784			43,836
Furniture, office equipment, and leasehold improvements		1,020,801			1,008,665			1,099,939			1,058,507
Manufacturing equipment and tooling		1,129,827			1,075,471			1,282,303			1,279,865
		2,436,536			2,353,096			2,382,242			2,563,496
Less: accumulated depreciation		(1,641,052	)		(1,516,813	)		(1,766,687	)		(1,704,715	)
Property and equipment, net	$	795,484		$	836,283		$	615,555		$	858,781

On May 21, 2019, the Company sold the house it owned for $0.2 million.

Depreciation expense was ~~$67,504and $70,154~~$75,073 and $67,504 for the three months ended June 30, ~~2018~~2019 and ~~2017,~~2018, respectively, and $148,588 and $133,984 ~~and$139,162~~ for the six months ended June 30, 2019 and 2018, ~~and 2017,~~ respectively.

~~- 8 -~~

NOTE 4 LEGAL PROCEEDINGS

~~The Company is~~We are involved in several lawsuits with ~~its~~our principal competitor, EMED Technologies ~~Corp.~~Corporation (“EMED”)~~, wherein~~. EMED has alleged ~~the Company’s~~that our needle sets infringe various patents controlled by EMED. Certain of these lawsuits also allege antitrust violations, unfair business practices, and various other business tort claims. We are vigorously defending against all of the lawsuits brought by EMED. Although no assurances can be given, ~~the Company believes it likely that each of EMED’s patents at issue in these cases will be deemed invalid and that the Company will succeed on the merits with respect~~we believe we have meritorious defenses to all of ~~the other elements of the cases.~~EMED’s claims.

The initial case involving EMED was filed by ~~the Company~~us in the United States District Court for the Eastern District of California on September 20, 2013 (the “California case”), in response to a letter from EMED claiming patent infringement by ~~RMS,~~us, and ~~sought to establish~~seeking a declaratory judgment establishing the invalidity of the patent referenced in the letter – EMED’s US patent US 8,500,703 – ~~or “’703.~~“‘703.” EMED answered the complaint and asserted patent infringement of ~~’703~~the ‘703 patent and several counterclaims relating generally to claims of unfair business ~~practice counterclaims. The Company~~practices against us. We responded by adding several claims against EMED, generally relating to claims of unfair business ~~practice claims against EMED.~~practices on EMED’s part. Both parties have requested injunctive relief and monetary damages in unspecified amounts. On June 16, 2015, the California court entered a preliminary injunction against RMS Medical making certain statements regarding what products were cleared by the FDA for use, or could be safely used, with RMS Medical’s Freedom60 pump, without voiding the product warranty.

- 9 -

On August 22, 2017, the Company filed a motion in this California case seeking a Preliminary Injunction prohibiting EMED from making false statements and claims regarding the products of both companies. The motion has now been fully briefed, and the parties are awaiting action by the Court.

~~Earlier, on~~ September 11, 2015, ~~the Company~~we requested an ex parte reexamination of the ~~’703~~‘703 patent by the US Patent and Trademark Office ~~(USPTO)~~(“USPTO”). The ex parte reexamination resulted in a Final Office Action dated July 19, 2017 rejecting all ~~EMED~~of EMED’s claims ofin the patent. On January 25, 2018, EMED filed an Appeal Brief with a Petition for Revival, which was accepted. On April 9, 2018, the USPTO denied EMED’s request for reconsideration of the order rejecting all claims in the ‘703 patent. On June 26, 2019, the Examiner responded to EMED’s appeal brief and maintained all of the ~~ex parte reexamination is ongoing.~~final rejections. Both the California case and EMED’s appeal of the USPTO rejections are pending.

The second court case was filed by EMED in the United States District Court for the Eastern District of Texas on June 25, 2015, claiming patent infringement ofon another of its patents (US 8,961,476 – ~~“’476”~~“‘476”), by ~~the Company’s~~our needle sets, and seeking unspecified monetary ~~damages.~~damages (“ED Texas ‘476 matter”). This ~~’476~~‘476 patent is related to the ~~’703~~now rejected EMED ‘703 patent.

On September 17, 2015, ~~the Company~~we requested an inter partes review (“IPR”) of ~~’476,~~the ‘476 patent, and in response to ~~the Company’s~~our request, the Court entered an order staying the ~~second case~~ED Texas ‘476 matter until after the Patent Trial and Appeal Board (“PTAB”) of the USPTO made a decision regarding the validity of the patent. On January 12, 2017, the PTAB issued its Final Written Decision in ~~RMS’s~~our favor, invalidating all but one (“dependent Claim 9”) of the claims in ~~this~~the ‘476 patent. ~~(The Company believes the remaining claim is not independently material to any of EMED’s litigation claims or RMS’s rights.)~~ EMED appealed the PTAB’s ruling to the United States Court of Appeals for the Federal Circuit, which affirmed the PTAB’s Final Written Decision in ~~the Company’s~~our favor on April 3, 2018. On April 18, 2018, EMED filed a petition for en banc ~~rehearing. The second court case in~~rehearing, which was denied. On August 16, 2018, EMED petitioned the ~~Eastern District~~United States Supreme Court for a Writ of ~~Texas remains stayed pending EMED’s exhaustion of its rights of judicial~~Certiorari to review ofthe Federal Circuit’s upholding the PTAB’s ~~decision.~~Final Written Decision. On October 29, 2018 the United States Supreme Court denied EMED’s Petition for a Writ of Certiorari, thus finally affirming the PTAB’s invalidation of ‘476, save for one dependent claim.

Following the PTAB’s Final Written Decision in the IPR ~~of ’476,~~regarding the ‘476 patent, EMED filed a new patent application claiming priority back to the application that issued as ~~’703~~‘703, which is the patent at issue in the California case. Submitted for accelerated examination, this new application issued as US 9,808,576 – ~~“’576”~~“‘576” on November 7, 2017. On this same date, EMED filed a new case ~~(third case)~~(the “third case”) in the United States District Court for the Eastern District of Texas claiming patent infringement of ~~’576,~~‘576, also directed to ~~the Company’s~~our needle sets, and seeking unspecified damages and a preliminary injunction against ~~the Company’s~~ marketing and sales of ~~its~~our needle sets. ~~RMS has~~We filed a Motion to Dismiss or Transfer Venue to the ~~Southern~~United States District of New York, as RMS has no physical or direct presence in the Eastern District of Texas. RMS also filed an opposition to EMED’s preliminary injunction motion, to which EMED did not file a reply. The Eastern District of Texas has now ordered the case moved toCourt for the Southern District of New York (“SDNY”), which has ~~now occurred.~~resulted in the transfer of the third case to SDNY (“SDNY ‘576 matter”).

~~On May 4, 2018~~The SDNY ‘576 matter is proceeding with the ~~Company requested an inter parties review (“IPR”)~~Court agreeing with RMS Medical’s proposal to brief summary judgment of ~~’576~~non-infringement now, and ~~EMED’s response is due in mid-August. Upon the submission of that Response, the Company intends to Move~~if needed it will consider setting a schedule for ~~Stay of the ’576 Southern District of New York matter.~~

~~EMED has petitioned the Eastern District of Texas for right to move the ’476 matter to the Southern District of New York~~discovery and for leave to amend the original complaint, but neither request is believed likely to succeed as both issues are years past statutory deadlines and at odds with prior statements made by EMED in this matter.trial.

On April 23, 2018, EMED filed a new ~~Civil Case~~civil case (the “fourth case”) against us in the United States District Court for the Eastern District of Texas asserting antitrust, defamation and unfair business practice claims, and seeking unspecified damages, similar to those previously presented in the ~~first~~California case, described above. The ~~Company~~fourth case also names Andrew Sealfon, then President and CEO of RMS Medical, individually as a defendant. As the result of a hearing on November 14, 2018, on December 7, 2018 the Court entered an order transferring the fourth case to the United States District Court for the Eastern District of California (the “California Court”). The fourth case is in a preliminary motion phase and ultimately expected to be coordinated or consolidated with the California case, or dismissed, as the California Court sees fit.

At the same hearing on November 14, 2018, the Texas Court granted EMED leave to amend its infringement contentions, following the IPR decision invalidating all but one claim of the ‘476 patent, in order to assert infringement of that sole remaining claim, namely dependent Claim 9. The Texas Court’s order allowing EMED’s amendment of its infringement contentions against us was entered on December 7, 2018.

The ED Texas ‘476 matter proceeded under EMED’s amended infringement contention to incorporate the surviving dependent Claim 9, which incorporates Claims 1 and 8 of the ‘476 patent, meaning that, to prove infringement on the part of us, EMED must prove more elements of infringement than it originally charged against us. In April 2019, EMED served its damages expert’s report opining that EMED’s past infringement damages amount to $1.5 million, and in May RMS Medical served its damages expert’s rebuttal report opining that EMED’s expert miscalculated damages which if properly calculated would amount to less than $100,000. The Texas Court had set a trial date of August 19, 2019 for the trial of the ED Texas ‘476 matter. On June 24, 2019, the Texas Court Magistrate Judge issued a Report and Recommendation decision finding no infringement, literally or under the doctrine of equivalents, by RMS Medical’s accused products. EMED filed its objections on June 26, 2019. On June 28, 2019 the United States District Judge for the Eastern District of Texas issued a Final Judgment in favor of RMS Medical and adopted the decision of the Magistrate Judge that was issued on June 24, 2019, overruled EMED’s objections, awarded court costs to RMS Medical, and dismissed the case. A final judgment has been entered. RMS Medical has submitted its Bill of Costs for approximately $16,000 and moved to declare the case exceptional and for recovery of its attorney fees and expenses, which could be material, in defense of EMED’s assertion of the ‘476 Patent. EMED has objected to our Bill of Costs and filed a ~~Motion~~notice of appeal of the non-infringement judgment to ~~Dismiss~~the Court of Appeals for the Federal Circuit.

- 10 -

As is required by the respective Courts in both the SDNY ‘576 matter and the ED Texas ‘476 matter, the parties are ~~awaiting~~engaging in settlement discussions and have conducted a ~~decision by the Court.~~court-sponsored mediation session, which did not result in settlement.

Although ~~the Company believes it~~we believe RMS Medical has meritorious claims and defenses in ~~these~~all of the above-described actions and proceedings, their outcomes cannot be predicted with any certainty. If any of these actions against ~~the Company~~us are successful, they could have a material adverse effect on ~~the Company’s~~our business, results of operations, financial condition and cash flows.

~~- 9 -~~

~~NOTE 5 STOCKHOLDERS’ EQUITY~~

On June 29, 2016, RMS’s Board of Directors authorized the Company to make open market purchases of up to 2,000,000 shares of the Company’s outstanding Common Stock. The purchases are made through a broker designated by the Company, with price, timing and volume restrictions based on average daily trading volume, consistent with the rules of the Securities and Exchange Commission for such repurchases. As of June 30, 2018, the Company had repurchased 396,606 shares at an average price of $0.45. The management of the Company has decided to discontinue repurchasing its outstanding common stock under the program for an undetermined period of time to utilize cash for capital investments needed to expand the business.

NOTE 65 STOCK-BASED COMPENSATION

On June 29, 2016, the Board of Directors amended the 2015 Stock Option Plan (the “Plan”) authorizing the Company to grant awards to certain executives, key employees, and consultants under the ~~plan at fair market value,~~Plan, which was approved by shareholders at the Annual Meeting held on September 6, 2016. The total number of shares of Common Stock, with respect to which awards may be granted pursuant to the Plan, ~~shall~~may not exceed ~~4,000,000 shares.~~6,000,000 pursuant to an amendment to the Plan approved by shareholders on April 23, 2019 at the 2019 Annual Meeting of Shareholders.

On June 3, 2019, under the Plan, the Company granted 1,000,000 incentive stock options to Donald Pettigrew, the Company’s President and Chief Executive Officer, whose vesting is contingent upon meeting net sales targets by each of the next three fiscal years through December 31, 2022.

As of June 30, ~~2018, there were~~2019, the Company had 3,654,000 options outstanding ~~931,000 options awarded~~ to certain executives, key employees and ~~advisory board members~~consultants under the ~~Plan.~~Plan, of which 1,300,000 were issued during the six months ended June 30, 2019. Additionally, the Company had 1,000,000 performance based options outstanding as of June 30, 2019 to its President and Chief Executive Officer under the Plan, of which all were issued during the three months ending June 30, 2019.

On ~~October 21, 2015,~~February 20, 2019, the Board of Directors of the Company approved an increase in compensation for each non-employee director ~~compensation~~from $25,000 to $50,000 annually effective January 1, 2019 and an additional $10,000 annually for the chair of ~~$25,000~~ each ~~annually,~~Board committee effective February 20, 2019, in each case to be paid quarterly half in cash and half in common stock ~~beginning September~~at the end of each fiscal quarter.

Pursuant to Daniel S. Goldberger’s employment agreement dated October 12, 2018, on February 1, ~~2015.~~2019, when Donald B. Pettigrew was appointed to President and Chief Executive Officer, Mr. Goldberger was awarded a performance bonus in the amount of $270,000 to be paid half in cash and half in stock on April 1, 2019. The number of shares that were issued totaled 90,604 and was based upon the closing price of the Common Stock of the Company on February 1, 2019 as reported by the OTCQX. These shares were issued on April 3, 2019.

2015 STOCK OPTION PLAN, as amended

Time Based Share Options

The per share weighted average fair value of stock options granted during the six months ended June 30, ~~2018~~2019 and June 30, ~~2017~~2018 was ~~$0.75and $0.25,~~$1.16 and $0.75, respectively. The fair value of each award is estimated on the grant date using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in the six months ended June 30, ~~2018~~2019 and June 30, ~~2017.~~2018. Historical information was the primary basis for the selection of the expected volatility, expected dividend yield and the expected lives of the options. The risk-free interest rate was selected based upon yields of the U.S. Treasury issues with a term equal to the expected life of the option being ~~valued:~~valued.


	June 30,				June 30,
	2018		2017		2019		2018

Dividend yield		0.00%		0.00%		0.00%		0.00%
Expected Volatility		65.2%		70.9-72.20%		58.9% - 60.3%		65.2%
Weighted-average volatility		—		—		—		—
Expected dividends		—		—		—		—
Expected term (in years)		5 Years		5 Years		10 Years		5 Years
Risk-free rate		2.80%		2.36-2.48%		2.12 - 2.72%		2.80%

- 11 -

The following table summarizes the status of the Plan:


	Six months Ended June 30,								Six months Ended June 30,
	2018			2017					2019			2018
	Shares	Weighted Average Exercise Price		Shares		Weighted Average Exercise Price			Shares	Weighted Average Exercise Price		Shares		Weighted Average Exercise Price

Outstanding at January 1	1,038,000	$	0.41		905,000	$	0.37		2,419,000	$	1.00		1,038,000	$	0.41
Granted	18,000	$	1.33		518,000	$	0.41		1,300,000	$	1.66		18,000	$	1.33
Exercised	125,000	$	0.41		—	$	—		65,000	$	0.38		125,000	$	0.41
Forfeited	—	$	—		310,000	$	0.36		—	$	—		—	$	—
Outstanding at June 30	931,000	$	0.43		1,113,000	$	0.39		3,654,000	$	1.24		931,000	$	0.43
Options exercisable at June 30	656,885	$	0.39		538,000	$	0.38		804,260	$	0.63		656,885	$	0.39
Weighted average fair value of options granted during the period									—	$	1.16		—	$	0.75
Stock-based compensation expense	—	$	26,670		—	$	(26,021	)	—	$	274,731		—	$	26,670

~~- 10 -~~

Total stock-based compensation expense ~~net of estimated forfeitures for stock option awards~~ totaled ~~$26,670~~$274,731 and ~~($26,021)~~$26,670 for the six months ended June 30, 2019 and 2018, ~~and June 30, 2017,~~ respectively. Cash received from option exercises for the six months ended June 30, 2019 and 2018 was $24,700 and ~~2017 was~~ $51,250, ~~and zero,~~ respectively.

The weighted-average grant-date fair value of options granted during the six months ended June 30, 2019 and 2018, was $1.16 and ~~June 30, 2017, was~~ $0.75, ~~and $0.25,~~ respectively. The total intrinsic value of options exercised during the six months ended June 30, 2019 and 2018, was $12,796 and ~~June 30, 2017, was~~ $30,664, ~~and zero,~~ respectively.

The following table presents information pertaining to options outstanding at June 30, ~~2018:~~2019:


Range of Exercise Price	Number Outstanding	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price		Number Outstanding	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price

$0.36 - $1.33	931,000	5 years	$	0.43	656,885	$	0.39
$0.36 - $2.09								3,654,000	5-10 years	$	1.24	804,260	$	0.63

As of June 30, ~~2018,~~2019, there was ~~$64,507~~$2,308,052 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plan. That cost is expected to be recognized over a weighted-average period of 1941 months. The total fair value of shares vested as of June 30, 2019 and 2018, was $313,714 and $135,979, respectively.

Performance Based Share Options

The per share weighted average fair value of stock options granted during the six months ended June 30, 2019 and 2018 was $1.16 and zero, respectively. The fair value of each award is estimated on the grant date using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in the six months ended June 30, 2019 and June 30, ~~2017,~~2018. Historical information was ~~$135,979~~the primary basis for the selection of the expected volatility, expected dividend yield and ~~$107,732,~~the expected lives of the options. The risk-free interest rate was selected based upon yields of the U.S. Treasury issues with a term equal to the expected life of the option being valued.


	June 30,
	2019		2018

Dividend yield		0.00%		—
Expected Volatility		58.9%		—
Weighted-average volatility		—		—
Expected dividends		—		—
Expected term (in years)		10 Years		—
Risk-free rate		2.07%		—

- 12 -

The following table summarizes the status of the Plan:


	Six months Ended June 30,
	2019			2018
	Shares	Weighted Average Exercise Price		Shares		Weighted Average Exercise Price

Outstanding at January 1	—	$	—		—	$	—
Granted	1,000,000	$	1.70		—	$	—
Exercised	—	$	—		—	$	—
Forfeited	—	$	—		—	$	—
Outstanding at June 30	1,000,000	$	1.70		—	$	—
Options exercisable at June 30	—	$	—		—	$	—
Weighted average fair value of options granted during the period	—	$	1.16		—	$	—
Stock-based compensation expense	—	$	41,909		—	$	—

Total performance stock-based compensation expense totaled $41,909 and zero for the six months ended June 30, 2019 and 2018, respectively.

The weighted-average grant-date fair value of options granted during the six months ended June 30, 2019 and June 30, 2018, was $1.16 and zero, respectively.

The following table presents information pertaining to performance based options outstanding at June 30, 2019:


Range of Exercise Price	Number Outstanding	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price

$1.70	1,000,000	10 years	$	1.70	—	$	1.70

As of June 30, 2019, there was $1,120,652 of total unrecognized compensation cost related to non-vested performance share option based compensation arrangements granted under the Plan. That cost is expected to be recognized over a weighted-average period of 31 months. The total fair value of shares vested as of June 30, 2019 and 2018 was zero for both periods.

NOTE 76 DEBT OBLIGATIONS

On February 8, 2018, the Company executed a Promissory Note with KeyBank National Association (“KeyBank”) in the amount of $1.5 million as a variable rate revolving line of credit loan due on demand with an interest rate of ~~Libor~~LIBOR plus 2.25%, collateralized with a certificate of deposit in the amount of $1.5 million. The Company entered into this arrangement to establish a credit lending history and, in the event needed, to have additional cash on hand for future expansion. On September 25, 2018, KeyBank released the certificate of deposit as collateral for the loan and the Company executed a Commercial Security Agreement as collateral for the loan. As of June 30, ~~2018~~2019, the Company has no outstanding amounts against the line of credit.

NOTE 7 LEASES

We have finance and operating leases for our corporate office and certain office and computer equipment. Our leases have remaining lease terms of 1 to 3 years, some of which include options to extend the leases annually and some with options to terminate the leases within 1 year.

- 1113 -

The components of lease expense were as follows:


	Three Months Ended June 30, 2019		Six Months Ended June 30, 2019

Operating lease cost	$	37,921	$	73,750

Finance lease cost:
Amortization of right-of-use assets	$	1,061	$	2,121
Interest on lease liabilities		59		131
Total finance lease cost	$	1,120	$	2,252

Supplemental cash flow information related to leases was as follows:


	Three Months Ended June 30, 2019		Six Months Ended June 30, 2019

Cash paid for amounts included in the measurement of lease liabilities:
Finance cash flows from finance leases	$	1,041	$	2,069
Finance lease cost:
Amortization of right-of-use assets	$	1,061	$	2,121
Interest on lease liabilities		59		131
Total finance lease cost	$	1,120	$	2,252

Supplemental balance sheet information related to leases was as follows:


	Six Months Ended June 30, 2019
Operating Leases
Operating lease right-of-use assets	$	439,782

Operating lease current liabilities		133,417
Operating lease long term liabilities		306,365
Total operating lease liabilities	$	439,782

Finance Leases
Property and equipment, at cost	$	6,363
Accumulated depreciation		2,121
Property and equipment, net	$	4,242

Finance lease current liabilities		4,295
Finance lease long term liabilities		—
Total finance lease liabilities	$	4,295


		Six Months Ended June 30, 2019
Weighted Average Remaining Lease Term
Operating leases		3 Years
Finance leases		1 Year

Weighted Average Discount Rate
Operating leases		4.75%
Finance leases		4.75%

- 14 -

Maturities of lease liabilities are as follows:


Year Ending December 31,	Operating Leases			Finance Leases
2019	$	75,843		$	2,200
2020		151,685			2,206
2021		149,476			—
2022		97,256			—
Total lease payments		474,260			4,406
Less imputed interest		(34,478	)		(111	)
Total	$	439,782		$	4,295

PART I – ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

This Quarterly Report on Form 10-Q contains certain “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995) and information relating to us that are based on the beliefs of the management, as well as assumptions made and information currently available.

Our actual results may vary materially from the forward-looking statements made in this report due to important factors such as uncertainties associated with future operating results, unpredictability related to Food and Drug Administration regulations, introduction of competitive products, acceptance of and demand for new and existing products, ability to penetrate new markets, success in enforcing and obtaining patents, reimbursement related risks, government regulation of the home health care industry, success of the research and development effort, expanding the market of FREEDOM60^®demand in the SCIg market, availability of sufficient capital if or when needed, dependence on key personnel and the outcome of litigation. When used in this report, the words “estimate,” “project,” “believe,” “may,” “will,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements. Such statements reflect current views with respect to future events based on currently available information and are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to release publicly any revision to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Throughout this report, “RMS Medical,” the “Company,” “we,” “us” and “our” refer to Repro Med Systems, Inc.

OVERVIEW

~~Net~~The second quarter of 2019 ended with record net sales ~~increased 17.6% for the three months ended June 30, 2018, as~~results of $5.3 million, an increase of 18.8% compared with the same period last ~~year. The increase in net sales was~~year, driven by ~~higher needle set~~increased volume in needles, tubing and pump sales ~~which we~~domestically. We believe ~~was bolstered by~~ the ~~FDA clearance for~~growth continues to be the ~~RMS “Integrated Catch-Up Freedom Syringe Driver Infusion System” on August 31, 2017, which includes both subcutaneous medications, specifically immunoglobulins~~result of growth in diagnosis of primary immunodeficiency diseases (“PIDD”) and ~~intravenous medications, such as antibiotics as well as sales from~~expansion into the ~~recently FDA approved first use of immunoglobulin~~neurology market with expanded Hizentra® indication for chronic inflammatory demyelinating polyneuropathy (“CIDP”) ~~indication~~. Our gross margin percentage improved four percentage points versus the same period last year mostly due to increased sales with improved production and the same labor. We had lower net income of $0.1 million for period ended June 30, 2019, compared with $0.5 million for the ~~subcutaneous drug Hizentra®. Net sales during~~previous year mostly due to increased legal fees for litigation activity and higher salary and related expenses resulting from the ~~period included approximately $0.3~~executive management changes and recently announced new hires. The Company also sold the house it owned which generated $0.2 million of revenue related to one-time sales to support the clinical activities for pharmaceutical companies. Net income for the period increased three-fold to $0.5 million, or 10.6% of net sales, which compares with $0.1 million reported during the second quarter of 2017. Higher net sales combined with improved gross profits on relatively flat operating expenses and a favorable tax rate change contributed to the increase in ~~profitability.~~cash proceeds.

- 15 -

RESULTS OF OPERATIONS

Three months ended June 30, ~~2018~~2019 compared to June 30, ~~2017~~2018

Net Sales

The following table summarizes our net sales for the three months ended June 30, ~~2018~~2019 and ~~2017:~~2018:


	Three Months Ended June 30,				Change from Prior Year			% of Sales		Three Months Ended June 30,				Change from Prior Year					% of Sales
	2018		2017		$		%	2018	2017	2019		2018		$			%		2019	2018
Sales
Domestic	$	3,582,392	$	2,988,833	$	593,559	19.9%	79.6%	78.0%	$	4,569,226	$	3,582,392	$	986,834		27.6%		85.4%	79.6%
International		919,934		840,624		79,310	9.4%	20.4%	22.0%		779,586		919,934		(140,348	)	(15.3%	)	14.6%	20.4%
Total	$	4,502,326	$	3,829,457	$	672,869	17.6%			$	5,348,812	$	4,502,326	$	846,486		18.8%

Total net sales increased ~~$0.7~~$0.8 million or ~~17.6%~~18.8% for the three ~~monthsended~~months ended June 30, ~~2018~~2019 compared with the same period last year. This growth was driven ~~mostly~~domestically by increased volume in ~~domestic~~ needle, tubing and pump sales. We believe ~~our 510(k) clearance described above contributed~~the growth continues to be due to growth in the ~~increase, as well as~~diagnosis of PIDD and expansion into the neurology market with the expanded Hizentra® indication for CIDP. Internationally, net sales were down, mostly due to ~~our pharmaceutical partners for~~a clinical ~~trials, which added $0.3 million for the three months.~~trial last year.

~~- 12 -~~

Gross Profit

Our gross profit for the three months ended June 30, ~~2018~~2019 and ~~2017~~2018 is as follows:


	Three Months Ended June 30,				Change from Prior Year			Three Months Ended June 30,				Change from Prior Year
	2018		2017		$		%	2019		2018		$		%
Gross Profit	$	2,739,584	$	2,297,299	$	442,285	19.3%	$	3,475,664	$	2,739,584	$	736,080	26.9%
Stated as a Percentage of Net Sales		60.8%		60.0%					65.0%		60.9%

Gross profit increased ~~$0.4~~$0.7 million or ~~19.3%~~26.9% in the three months ended June 30, ~~2018,~~2019, compared to the same period in ~~2017.This~~2018. This increase in the quarter was mostly driven by the increase in net sales and leveraged production costs on higher net sales.

Selling, general and administrative and Research and development

Our selling, general and administrative expenses and research and development costs for the three months ended June 30, ~~2018~~2019 and ~~2017~~2018 are as follows:


	Three Months Ended June 30,				Change from Prior Year					Three Months Ended June 30,				Change from Prior Year
	2018		2017		$			%		2019		2018		$		%
Selling, general and administrative	$	2,022,631		2,005,336	$	17,295		0.9%		$	3,175,382		2,022,631	$	1,152,751	57.0%
Research and development		23,963		24,840		(877	)	(3.5%	)		178,235		23,963		154,272	643.8%
	$	2,046,594		2,030,176	$	16,418		0.8%		$	3,353,617		2,046,594	$	1,307,023	63.9%
Stated as a Percentage of Net Sales		45.5%		53.0%							62.7%		45.5%

Selling, general and administrative ~~expensesduring~~expenses during the three months ended June 30, ~~2018 were nearly even with~~2019 increased $1.2 million, or 57.0%, over the same period last ~~year. This resulted from higher regulatory salary and benefits~~year due to ~~meet our compliance activities, the addition of~~increased litigation activity resulting in a clinical and medical affairs associate and consulting for FDA submissions and international registrations in aggregate $0.2 million. Additionally we incurred higher consulting and recruiting fees for investor relations and the chief executive officer search of $0.1 million. Mostly offsetting these increases were lower legal fees of $0.1$1.0 million ~~and lower~~increase. Executive salary and related benefits ~~expense of $0.2~~increased $0.3 million due to the ~~termination~~addition of the ~~chief operating officer last~~Executive Chairman of the Board, our new President and Chief Executive Officer and other executive changes. We also added a Vice President of Medical Affairs to the team, adding $0.1 million year ~~and decreased headcount~~over year. Offsetting these increases was attrition in sales and ~~marketing.~~marketing and regulatory in aggregate totaling $0.3 million.

Research and development expenses ~~are nearly even with the same period~~increased $0.2 million over last year due to increased headcount and expanded product development initiatives compared to last year. ~~We hired a new engineer in April 2018.~~

Depreciation and amortization

Depreciation and amortization expense ~~decreased~~increased by ~~1.0 %~~13.4% to $86,169 in the three months ended June 30, 2019 compared with $75,978 in the three months ended June 30, ~~2018 compared with $76,781~~2018. We continue to invest in ~~the three months ended June 30, 2017, as a result of decreased depreciation as more~~capital assets, ~~become fully depreciated offset by a continued investment in~~mostly related to production equipment, computer equipment and ~~increased amortization expense of new~~leasehold improvements, and in patent applications and ~~maintenance of existing patents.~~their maintenance.

- 16 -

Net Income


	Three Months Ended June 30,				Change from Prior Year		Three Months Ended June 30,				Change from Prior Year
	2018		2017		$		2019		2018		$			%
Net Income	$	475,723		148,472		327,251	$	78,183	$	475,723	$	(397,540	)	(83.6%	)
Stated as a Percentage of Net Sales		10.6%		3.9%				1.5%		10.6%

Our net income for the three months ended June 30, ~~2018~~2019 was ~~$0.5~~$0.1 million compared to ~~$0.1~~$0.5 million for the three months ended June 30, ~~2017,~~2018. The decline is mostly driven by ~~higher net sales, level operating expenses~~the increase in legal fees and ~~the impact of the new lower income tax rate. Partially offsetting this was a negative foreign exchange effect of $54,508 versus last year.~~selling general and administrative fees as described above.

~~- 13 -~~

Six months ended June 30, ~~2018~~2019 compared to June 30, ~~2017~~2018

Net Sales

The following table summarizes our net sales for the six months ended June 30, ~~2018~~2019 and ~~2017:~~2018:


	Six months Ended June 30,				Change from Prior Year			% of Sales		Six months Ended June 30,				Change from Prior Year			% of Sales
	2018		2017		$		%	2018	2017	2019		2018		$		%	2019	2018
Sales
Domestic	$	6,957,600	$	5,984,280	$	973,320	16.3%	81.5%	80.1%	$	8,452,791	$	6,957,600	$	1,495,191	21.5%	81.9%	81.5%
International		1,577,950		1,483,613		94,337	6.4%	18.5%	19.9%		1,870,299		1,577,950		292,349	18.5%	18.1%	18.5%
Total	$	8,535,550	$	7,467,893	$	1,067,657	14.3%			$	10,323,090	$	8,535,550	$	1,787,540	20.9%

Total net sales increased ~~$1.1~~$1.8 million or ~~14.3%~~20.9% for the six months ended June 30, ~~2018~~2019 driven largely by needle set sales. We believe ~~our 510(k) clearance described above contributed~~the growth is due to growth in the ~~increase, as well as sales to our pharmaceutical partners~~diagnosis of PIDD and expansion into the neurology market with expanded Hizentra® indication for ~~clinical trials which added $0.4 million for the six months.~~ CIDP.

Gross Profit

Our gross profit for the six months ended June 30, ~~2018~~2019 and ~~2017~~2018 is as follows:


	Six months Ended June 30,				Change from Prior Year			Six months Ended June 30,				Change from Prior Year
	2018		2017		$		%	2019		2018		$		%
Gross Profit	$	5,205,408	$	4,399,254	$	806,154	18.3%	$	6,523,618	$	5,205,408	$	1,318,210	25.3%
Stated as a Percentage of Net Sales		61.0%		58.9%					63.2%		61.0%

Gross profit increased ~~$0.8~~$1.3 million or ~~18.3%~~25.3% in the six months ended June 30, ~~2018,~~2019, compared to the same period last year. This increase was driven by the increase in net sales of ~~$1.1 million. Additionally,~~$1.8 million as well as leveraged production ~~operating efficiencies contributed to improved gross margin.~~costs on higher net sales.

Selling, general and administrative and Research and development

Our selling, general and administrative expenses and research and development costs for the six months ended June 30, ~~2018~~2019 and ~~2017~~2018 are as follows:


	Six months Ended September 30,				Change from Prior Year				Six months Ended September 30,				Change from Prior Year
	2018		2017		$			%	2019		2018		$		%
Selling, general and administrative	$	3,902,900	$	3,780,445	$	122,455		3.2%	$	6,152,765	$	3,902,900	$	2,249,865	57.7%
Research and development		33,811		70,746		(36,935	)	(52.2)%		280,194		33,811		246,383	728.7%
	$	3,936,711	$	3,851,191	$	85,520		2.2%	$	6,432,959	$	3,936,711	$	2,496,248	63.4%
Stated as a Percentage of Net Sales		46.1%		51.6%						62.3%		46.1%

- 17 -

Selling, general and administrative expenses increased ~~$0.1~~$2.2 million, or ~~3.2%~~57.7%, during the six months ended June 30, ~~2018~~2019 compared to the same period last ~~year. This resulted from higher regulatory salary~~year significantly due to increased litigation activity and ~~benefits to meet our compliance activities,~~legal support for the ~~addition~~filing of ~~a clinical~~the resale registration statement and ~~medical affairs associate and consulting fees for FDA submissions and international registrations in aggregate $0.3~~executive management changes matters totaling $1.5 million. ~~Additionally we incurred higher consulting and recruiting fees for investor relations and the chief executive officer search of $0.2 million. Mostly offsetting these increases were lower~~Executive salary and related benefits ~~expense of $0.4~~increased $0.9 million due to the ~~termination~~addition of the ~~chief operating officer last~~Executive Chairman of the Board, our new President and Chief Executive Officer and other executive changes, including a performance bonus payment to our former interim Chief Executive Officer in the amount of $0.3 million. We also added a Vice President of Medical Affairs to the team, adding $0.1 million year over year. Higher investor relation expenses and ~~decreased headcount~~director fees also contributed $0.2 million to the increase. Offsetting these increases was attrition in sales and ~~marketing.~~marketing and regulatory salary and related benefit expense in the amount of $0.4 million and lower executive recruiting fees of $0.1 million.

Research and development expense ~~decreased~~increased by ~~52.2%,~~$0.2 million primarily due to ~~attrition for the period~~increased headcount and expanded product development initiatives compared ~~with~~to last year. ~~We have since hired an engineer.~~

Depreciation and amortization

Depreciation and amortization expense ~~decreased~~increased by ~~0.7%~~12.8% to $169,820 in the six months ended June 30, 2019 compared with $150,556 in the six months ended June 30, ~~2018 compared with $151,662~~2018. We continue to invest in ~~the six months ended June 30, 2017as a result of decreased depreciation~~capital assets mostly related to production and computer equipment upgrades, as ~~more assets become fully depreciated offset by a continued investment~~well as in ~~production equipment, and increased amortization expense of new~~ patent applications and ~~maintenance of existing patents.~~their maintenance.

~~- 14 -~~

Net (Loss)/Income


	Six months Ended June 30,				Change from Prior Year		Six months Ended June 30,					Change from Prior Year
	2018		2017		$		2019			2018		$
Net Income	$	879,150	$	275,423	$	603,727
Net (Loss)/Income							$	(7,207	)	$	879,150	$	(886,357	)
Stated as a Percentage of Net Sales		10.3%		3.7%				(0.1%	)		10.3%

Our net ~~income~~loss for the six months ended June 30, ~~2018~~2019 was ~~$0.9 million~~($7,207) compared to a net income of ~~$0.3~~$0.9 million for the six months ended June 30, ~~2017.~~2018. This ~~$0.6~~$0.9 million ~~change~~decrease was ~~mostly a result of the increase in net sales, a 2.2% increase in~~driven by increased selling, general and administrative ~~and research and development~~ expenses, as described ~~above as well as a lower income tax rate. Partially offsetting this was a negative foreign exchange effect of $62,158 versus last year.~~above.

LIQUIDITY AND CAPITAL RESOURCES

Our principal source of liquidity is our cash of ~~$3.4~~$3.8 million as of June 30, ~~2018.~~2019. Additionally, we have a $1.5 million line of credit with no outstanding amounts against it. Our principal source of operating cash inflows is from sales of our products to customers. Our principal cash outflows relate to the purchase and production of inventory and related costs, selling, general and administrative expenses ~~capital expenditures~~ and ~~patent costs.~~professional fees.

We believe that as of June 30, ~~2018,~~2019, cash on hand and cash expected to be generated from future operating activities will be sufficient to fund our operations, including further research and development and capital expenditures, for the next 12 months. We believe ~~the FREEDOM System continues~~RMS Medical’s home infusion products continue to find a solid following in the ~~SCIg~~subcutaneous immunoglobulin (“SCIg”) market, ~~and this market is expected to continue to increase both domestically and internationally.~~

~~On February 8, 2018, the Company executed a Promissory Note with KeyBank National Association in the amount of $1.5 million~~ as ~~a variable rate revolving line of credit loan due on demand with~~well as, into new markets like neurology where Hizentra® received an interest rate of Libor plus 2.25%, collateralized with a certificate of deposit in the amount of $1.5 million. The Company entered into this arrangement to establish a credit lending history and, in the event needed, to have additional cash on handexpanded indication for ~~future expansion. As of June 30, 2018, the Company has no outstanding amounts against the line of credit.~~CIDP.

We continue to be in litigation with a competitor, EMED Technologies ~~Corporation~~Corp. (“EMED”) and have incurred a significant amount of legal fees in connection with that process. Although the Company believes it has meritorious claims and defenses in the actions and proceedings, their outcomes cannot be predicted with any certainty. If any of these actions against the Company are successful, they could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows.

Cash Flows

The following table summarizes our cash flows:

Six months Ended
June 30, 2018

Six months Ended
June 30, 2017

Net cash provided by/(used in) operating activities

$
955,787

$
(270,852
)
Net cash used in investing activities

$
(1,558,632
)
$
(143,979
)
Net cash provided by/(used in) financing activities

$
49,495

$
(19,844
)


	Six months Ended June 30, 2019			Six months Ended June 30, 2018
Net cash (used in)/provided by operating activities	$	(1,483,909	)	$	955,787
Net cash provided by/(used in) investing activities	$	1,532,487		$	(1,558,632	)
Net cash provided by financing activities	$	19,811		$	49,495

- 18 -

Operating Activities

Net cash used in operating activities of $1.5 million for the six months ended June 30, 2019 was mostly attributable to increased accounts receivable of $1.9 million as one of our major customer’s payment terms changed on January 1, 2019 from net 30 to net 60 days, and increased inventory of $0.5 million as we look to build stock to keep pace with sales growth. Partially offsetting these were our non-cash charges for stock based compensation of $0.5 million and depreciation and amortization of long lived tangible and intangible asset of $0.2 million.

Net cash provided by operating activities of $1.0 million for the six months ended June 30, 2018 was primarily the result of net income of $0.9 million, non-cash charges of $0.2 million for depreciation and amortization of long lived tangible and intangible assets and stock based compensation of $0.1 million, as well as an increase in accounts payable of $0.3 million due to higher supplier payables. Partially offsetting these were payments for insurance renewals, severance, bonus and sales commission payments.

~~Net~~Investing Activities

Our net cash ~~used in operating~~provided by investing activities of ~~$0.3~~$1.5 million for the six months ended June 30, ~~2017~~2019 was ~~primarily attributable to an increase in accounts receivable~~mostly the result of ~~$0.6~~the maturation of a certificate of deposit for $1.5 million and ~~a decrease in accounts payable~~the sale of ~~$0.5~~the house the Company owned for $0.2 million, ~~mostly due to the payment of legal fees in the period. Offsetting this was net income of $0.3 million, non-cash charges~~offset by capital expenditures and patent application and maintenance of $0.2 million for depreciation and amortization of long lived tangible, intangible assets and stock based compensation of $41,479, a decrease in inventory of $0.1 million and increase in tax liability resulting from increased profits.

~~- 15 -~~

~~Investing Activities~~

million. Our net cash used for investing activities of $1.6 million for the six months ended June 30, 2018 was mostly the result of the purchase of a certificate of deposit. ~~Net cash used in investing~~

Financing Activities

The $19,811 provided by financing activities ~~of $0.1 million~~ for the six months ended June 30, ~~2017 was primarily attributable to our investment in capital assets, mostly related to production~~2019 is a result of options exercised less payments for cancelled shares and ~~computer equipment, and for new patent applications and maintenance of existing patents.~~

~~Financing Activities~~

leased office equipment. Net cash provided by financing activities was $49,495 for the six months ended June 30, 2018 mostly ~~resulting~~resulted from the exercise of options. ~~Net cash used in financing activities was $19,844 for the six months ended June 30, 2017 mostly resulting from the cancellation of shares.~~

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13—Financial Instruments – Credit Losses (Topic 326); Measurement of Credit Losses on Financial Instruments, which amends guidance on reporting credit losses for assets held at amortized cost basis and available for sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available for sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. This ASU affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in this update are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption.

- 19 -

NON-GAAP FINANCIAL MEASURES

Management of the Company believes that investors’ understanding of the Company’s performance is enhanced by disclosing non-GAAP financial measures as a reasonable basis for comparison of the Company’s ongoing results of operations. These non-GAAP measures should not be considered a substitute for GAAP-basis measures and results. Our non-GAAP measures may not be comparable to non-GAAP measures of other companies. The table below provides a disclosure of these non-GAAP financial measures to the most closely analogous measure determined in accordance with GAAP.

Non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on our reported results and, therefore, should not be relied upon as the sole financial measures to evaluate our financial results. The non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial results.

We disclose and discuss Adjusted EBITDA as a non-GAAP financial measure in our public releases, including quarterly earnings releases, and other filings with the Securities and Exchange Commission. We define Adjusted EBITDA as earnings (net income) before interest, income taxes, depreciation and amortization, reorganization charges, litigation and stock option expenses. We believe that Adjusted EBITDA is used by investors and other users of our financial statements as a supplemental financial measure that, when viewed with our GAAP results and the accompanying reconciliation, we believe provides additional information that is useful to gain an understanding of the factors and trends affecting our business. We also believe the disclosure of Adjusted EBITDA helps investors meaningfully evaluate and compare our cash flow generating capacity from quarter to quarter and year to year. Adjusted EBITDA is used by management as a supplemental internal measure for planning and forecasting overall expectations and for evaluating actual results against such expectations. Because management uses Adjusted EBITDA for such purposes, the Company uses Adjusted EBITDA as a significant criterion for determining the amount of annual cash incentive compensation paid to our executive officers and employees. We have historically found that Adjusted EBITDA is superior to other metrics for our company-wide cash incentive program, as it is more easily explained and understood by our typical employee.

A reconciliation of our non-GAAP measures is below:


	Three Months Ended						Six Months Ended
Reconciliation of GAAP Net (Loss)/Income	June 30,						June 30,
to Non-GAAP Adjusted EBITDA:	2019			2018			2019			2018
GAAP Net Income/(Loss)	$	78,183		$	475,723		$	(7,207	)	$	879,150
Tax Expense		24,683			126,952			2,584			234,693
Depreciation/Amortization		86,169			75,978			169,820			150,556
Interest Income, Net		(18,243	)		(5,501	)		(35,723	)		(6,116	)
Reorganization Charges		—			78,646			354,926			151,197
Litigation		1,124,947			150,500			1,617,462			306,300
Stock Option Expense		194,765			29,487			316,640			56,670
Non-GAAP Adjusted EBITDA	$	1,490,504		$	931,785		$	2,418,502		$	1,772,450

Reorganization Charges. We have excluded the effect of Reorganization Charges in calculating our non-GAAP Adjusted EBITDA measure. We incurred significant expenses in connection with the recent termination and replacement of C-suite executives and senior management which we would not otherwise incur in periods presented as part of our continuing operations. Reorganization charges include costs related to the replacement of C-suite executives including a transition bonus and recruiting fees.

- 20 -

Litigation.We have excluded litigation expenses in calculating our non-GAAP Adjusted EBITDA measure. We continue to evaluate our business performance excluding litigation fees and we expect them to continue in future periods.

Stock Option Expense. We have excluded the effect of stock option expenses in calculating our non-GAAP Adjusted EBITDA measure. Although stock option compensation is a key incentive offered to our employees, we continue to evaluate our business performance excluding stock option compensation expenses. We record non-cash compensation expense related to grants of options and depending upon the size, timing and the terms of the grants, the non-cash compensation expense may vary significantly but will recur in future periods.

PART I – ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET ~~RISK.~~RISK

Not Applicable.

~~- 16 -~~

PART I – ITEM 4. CONTROLS AND ~~PROCEDURES.~~PROCEDURES

The Company’s management, including the Company’s Principal Executive Officer and Principal Financial Officer, ~~have~~has evaluated the effectiveness of the Company’s disclosure controls and procedures as such is defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based upon their evaluations, the Principal Executive Officer and Principal Financial Officer concluded that, as of the end of the period covered by this report, the Company’s disclosure controls and procedures were effective for the purpose of ensuring that the information required to be disclosed in the reports that the Company files or submits under the Exchange Act with the Securities and Exchange Commission (the “SEC”) (1) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (2) is accumulated and communicated to the Company’s management, including its Principal Executive Officer and Principal Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

There have been no changes in the Company’s internal control over financial reporting during the quarter ended June 30, ~~2018,~~2019, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are involved in several lawsuits with our principal competitor, EMED Technologies Corporation (“EMED”). EMED has alleged that our needle sets infringe various patents controlled by EMED. Certain of these lawsuits also allege antitrust violations, unfair business practices, and various other business tort claims. We are vigorously defending against all of the lawsuits brought by EMED. Although no assurances can be given, we believe we have meritorious defenses to all of EMED’s claims.

The initial case involving EMED was filed by us in the United States District Court for the Eastern District of California on September 20, 2013 (the “California case”), in response to a letter from EMED claiming patent infringement by us, and seeking a declaratory judgment establishing the invalidity of the patent referenced in the letter – EMED’s US patent 8,500,703 – “‘703.” EMED answered the complaint and asserted patent infringement of the ‘703 patent and several counterclaims relating generally to claims of unfair business practices against us. We responded by adding several claims against EMED, generally relating to claims of unfair business practices on EMED’s part. Both parties have requested injunctive relief and monetary damages in unspecified amounts. On June 16, 2015, the California court entered a preliminary injunction against RMS Medical making certain statements regarding what products were cleared by the FDA for use, or could be safely used, with RMS Medical’s Freedom60 pump, without voiding the product warranty.

On September 11, 2015, we requested an ex parte reexamination of the ‘703 patent by the US Patent and Trademark Office (“USPTO”). The ex parte reexamination resulted in a Final Office Action dated July 19, 2017, rejecting all of EMED’s claims in the patent. On January 25, 2018, EMED filed an Appeal Brief with a Petition for Revival, which was accepted. On April 9, 2018, the USPTO denied EMED’s request for reconsideration of the order rejecting all claims in the ‘703 patent. On June 26, 2019, the Examiner responded to EMED’s appeal brief and maintained all of the final rejections. Both the California case and EMED’s appeal of the USPTO rejections are pending.

The second court case was filed by EMED in the United States District Court for the Eastern District of Texas on June 25, 2015, claiming patent infringement on another of its patents (US 8,961,476 – “‘476”), by our needle sets, and seeking unspecified monetary damages (“ED Texas ‘476 matter”). This ‘476 patent is related to the now rejected EMED ‘703 patent.

- 21 -

On September 17, 2015, we requested an inter partes review (“IPR”) of the ‘476 patent, and in response to our request, the Court entered an order staying the ED Texas ‘476 matter until after the Patent Trial and Appeal Board (“PTAB”) of the USPTO made a decision regarding the validity of the patent. On January 12, 2017, the PTAB issued its Final Written Decision in our favor, invalidating all but one (“dependent Claim 9”) of the claims in the ‘476 patent. EMED appealed the PTAB’s ruling to the United States Court of Appeals for the Federal Circuit, which affirmed the PTAB’s Final Written Decision in our favor on April 3, 2018. On April 18, 2018, EMED filed a petition for en banc rehearing, which was denied. On August 16, 2018, EMED petitioned the United States Supreme Court for a Writ of Certiorari to review the Federal Circuit’s upholding the PTAB’s Final Written Decision. On October 29, 2018 the United States Supreme Court denied EMED’s Petition for a Writ of Certiorari, thus finally affirming the PTAB’s invalidation of ‘476, save for one dependent claim.

Following the PTAB’s Final Written Decision in the IPR regarding the ‘476 patent, EMED filed a new patent application claiming priority back to the application that issued as ‘703, which is the patent at issue in the California case. Submitted for accelerated examination, this new application issued as US 9,808,576 – “‘576” on November 7, 2017. On this same date, EMED filed a new case (the “third case”) in the United States District Court for the Eastern District of Texas claiming patent infringement of ‘576, also directed to our needle sets, and seeking unspecified damages and a preliminary injunction against marketing and sales of our needle sets. We filed a Motion to Dismiss or Transfer Venue to the United States District Court for the Southern District of New York (“SDNY”), which has resulted in the transfer of the third case to SDNY (“SDNY ‘576 matter”).

The SDNY ‘576 matter is proceeding with the Court agreeing with RMS Medical’s proposal to brief summary judgment of non-infringement now, and if needed it will consider setting a schedule for discovery and trial.

On April 23, 2018, EMED filed a new civil case (the “fourth case”) against us in the United States District Court for the Eastern District of Texas asserting antitrust, defamation and unfair business practice claims, and seeking unspecified damages, similar to those previously presented in the California case, described above. The fourth case also names Andrew Sealfon, then President and CEO of RMS Medical, individually as a defendant. As the result of a hearing on November 14, 2018, on December 7, 2018 the Court entered an order transferring the fourth case to the United States District Court for the Eastern District of California (the “California Court”). The fourth case is in a preliminary motion phase and ultimately expected to be coordinated or consolidated with the California case, or dismissed, as the California Court sees fit.

The ED Texas ‘476 matter proceeded under EMED’s amended infringement contention to incorporate the surviving dependent Claim 9, which incorporates Claims 1 and 8 of the ‘476 patent, meaning that, to prove infringement on the part of us, EMED must prove more elements of infringement than it originally charged against us. In April 2019, EMED served its damages expert’s report opining that EMED’s past infringement damages amount to $1.5 million, and in May RMS Medical served its damages expert’s rebuttal report opining that EMED’s expert miscalculated damages which if properly calculated would amount to less than $100,000. The Texas Court had set a trial date of August 19, 2019 for the trial of the ED Texas ‘476 matter. On June 24, 2019, the Texas Court Magistrate Judge issued a Report and Recommendation decision finding no infringement, literally or under the doctrine of equivalents, by RMS Medical’s accused products. EMED filed its objections on June 26, 2019. On June 28, 2019 the United States District Judge for the Eastern District of Texas issued a Final Judgment in favor of RMS Medical and adopted the decision of the Magistrate Judge that was issued on June 24, 2019, overruled EMED’s objections, awarded court costs to RMS Medical, and dismissed the case. A final judgment has been entered. RMS Medical has submitted its Bill of Costs for approximately $16,000 and moved to declare the case exceptional and for recovery of its attorney fees and expenses, which could be material, in defense of EMED’s assertion of the ‘476 Patent. EMED has objected to our Bill of Costs and has filed a notice of appeal of the non-infringement judgment to the Court of Appeals for the Federal Circuit.

As is required by the respective Courts in both the SDNY ‘576 matter and the ED Texas ‘476 matter, the parties are engaging in settlement discussions and have conducted a court-sponsored mediation session, which did not result in settlement.

Although we believe RMS Medical has meritorious claims and defenses in all of the above-described actions and proceedings, their outcomes cannot be predicted with any certainty. If any of these actions against us are successful, they could have a material adverse effect on our business, results of operations, financial condition and cash flows.

- 22 -

ITEM 1A. RISK FACTORS

Our operations and financial results are subject to various risks and uncertainties, including those described in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2018, which could adversely affect our business, financial condition, results of operations, cash flows, and the trading price of our common stock. There have been no material changes to our risk factors since our Annual Report on Form 10-K for the year ended December 31, 2018.

PART II – ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF ~~PROCEEDS.~~PROCEEDS

On October 21, 2015, the Board of Directors of the Company approved non-employee director compensation of $25,000 each annually, to be paid quarterly half in cash and half in common stock, beginning September 1, 2015. ~~The number~~On February 20, 2019, the Board of ~~shares~~Directors of the Company approved an increase in compensation for each non-employee director from $25,000 to $50,000 annually effective January 1, 2019, and an additional $10,000 annually for the chair of each Board committee effective February 20, 2019, in each case to be ~~issued each quarter is calculated based upon the closing price of the~~paid quarterly half in cash and half in common stock onat the ~~last day~~end of each fiscal ~~quarter as reported by the OTCQX.~~quarter. The Company issued ~~14,424~~an aggregate of 25,782 and ~~29,424~~34,696 shares of common stock to its non-employee directors during the three and six month period ended June 30, ~~2018,~~2019, respectively.

Pursuant to Daniel S. Goldberger’s employment agreement dated October 12, 2018, on February 1, 2019, when Donald B. Pettigrew was appointed to President and Chief Executive Officer, Mr. Goldberger was awarded a performance bonus in the amount of $270,000, half in cash and half in common stock, to be paid on April 1, 2019. The ~~Company issued 11,538 and 23,538~~number of shares of common stock ~~to Dr. Fred Ma, its Chief Medical Officer, under~~issued was 90,604 based upon the ~~terms of his employment agreement, during the three and six month periods ended June 30, 2018, respectively.~~

~~On June 29, 2016, RMS’s Board of Directors authorized the Company to make open market purchases of up to 2,000,000 shares~~closing price of the ~~Company’s outstanding~~ Common Stock. The purchases are made through a broker designated by the Company, with price, timing and volume restrictions based on average daily trading volume, consistent with the rules of the Securities and Exchange Commission for such repurchases. As of June, 2018, the Company had repurchased 396,606 shares at an average price of $0.45. There were no repurchases of common stock by the Company during the quarter ended June 30, 2018. The managementStock of the Company ~~has decided to discontinue repurchasing its outstanding Common Stock for an undetermined period of time to utilize cash for capital investments needed to expand~~on February 1, 2019 as reported by the ~~business. There is no expiration date to the repurchase plan.~~OTCQX.

On June 29, 2016, the Board of Directors amended the 2015 Stock Option Plan authorizing the Company to grant awards to certain employees under the plan at fair market value, which was approved by shareholders at the Annual Meeting held on September 6, 2016. The total number of shares of Common Stock, with respect to which awards may be granted pursuant to the Plan, shall not exceed 4,000,000 shares. As of June 30, ~~2018, there were~~2019, the Company had 4,654,000 options outstanding ~~931,000 options awarded~~ to certain executives, key employees and ~~advisory board members~~consultants under its 2015 Stock Option Plan, as amended (the “Plan”), of which 1,250,000 were issued during the three months ended June 30, 2019. There are 6,000,000 options authorized for issuance under the Plan. During the three months ended June 30, 2019, 65,000 options were exercised at an exercise price of $0.38, totaling $24,700.

The following table describes the options issued to Company executives and key consultants for the six months ended June 30, 2019:


Date Issued	Options Awarded	Vesting Schedule	Exercise Price $
1/29/2019	500,000	20% annually on anniversary date	1.57
1/29/2019	300,000	25% annually on anniversary date	1.57
2/26/2019	250,000	62,500 on first anniversary date, 31,250 every six months thereafter	1.57
6/3/2019	1,000,000	Vest 33% annually based on net sales performance targets	1.70
6/4/2019	50,000	Vest 25% annually on anniversary date	1.73
6/10/2019	200,000	Vest 25% annually on anniversary date	2.09

All of the securities issued by the Company as described in this Item were issued in reliance on the exemption from registration under Section 4(2) under the Securities Act of 1933, as amended.

PART II – ITEM 6. EXHIBITS.


31.1	Certification of Principal Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act 2002

31.2	Certification of Principal Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act 2002

32.1	Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 2002

32.2	Certification of Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 2002

101*	Interactive Data Files of Financial Statements and Notes.

* In accordance with Regulation S-T, the Interactive Data Files in Exhibit 101 to the Quarterly Report on Form 10-Q shall be deemed “furnished” and not “filed”.

- 1723 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	REPRO MED SYSTEMS, INC.

August ~~6, 2018~~7, 2019	/s/ ~~Daniel S. Goldberger~~Donald B. Pettigrew
	~~Daniel S. Goldberger, Chairman of the Board, Interim~~Donald B. Pettigrew, President and Chief Executive Officer

August ~~6, 2018~~7, 2019	/s/ Karen Fisher
	Karen Fisher, Chief Financial Officer and Treasurer

- 1824 -


	Six months Ended June 30, 2018			Six months Ended June 30, 2017
Net cash provided by/(used in) operating activities	$	955,787		$	(270,852	)
Net cash used in investing activities	$	(1,558,632	)	$	(143,979	)
Net cash provided by/(used in) financing activities	$	49,495		$	(19,844	)